Negative results from Phase III DANUBE trial of durvalumab in metastatic bladder cancer

Durvalumab monotherapy did not improve overall survival (vs. standard of care) for patients whose tumours expressed high levels of PD-L1, and use of durvalumab in combination with tremelimumab missed its primary endpoint in patients regardless of their PD-L1 expression.